Browsing Tag
VGA039
3 posts
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
June 8, 2026
Can VGA039 become a once-monthly standard of care for von Willebrand disease?
Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care.
December 8, 2025
VGA039 : Vega Therapeutics begins clinical trial of Von Willebrand disease candidate
Vega Therapeutics has launched the clinical trial program for VGA039, an investigational antibody therapy for Von Willebrand disease…
April 9, 2023